(S)-1-((4-(2-(4-aminophenyl)-1H-imidazol-1-yl)pyrimidin-2-yl)amino)propan-2-ol | 1220701-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-1-((4-(2-(4-aminophenyl)-1H-imidazol-1-yl)pyrimidin-2-yl)amino)propan-2-ol
• CAS: 1220701-21-2
• 化学式: C₁₆H₁₈N₆O
• 分子量: 310.359
• InChiKey: QUKDNMFTVDWSNC-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  101.88
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  4-吗啉代-3-(三氟甲基)苯甲酸 、 (S)-1-((4-(2-(4-aminophenyl)-1H-imidazol-1-yl)pyrimidin-2-yl)amino)propan-2-ol 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-N-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines

  摘要：

  The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 mu M, respectively) and turned out to be a selective and potent CRAF inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.064
• 作为产物：
  描述：

  (S)-1-((4-(2-(4-nitrophenyl)-1H-imidazol-1-yl)pyrimidin-2-yl)amino)propan-2-ol 在 palladium 10% on activated carbon 作用下， 以 甲醇 为溶剂， 反应 6.0h， 生成 (S)-1-((4-(2-(4-aminophenyl)-1H-imidazol-1-yl)pyrimidin-2-yl)amino)propan-2-ol
  参考文献：
  名称：

  Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines

  摘要：

  The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 mu M, respectively) and turned out to be a selective and potent CRAF inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.064